Table 3.

Association between ACPA/RF status at baseline and CDAI over time using GLMMs

Regression coefficients (standard error), p-value
All patients (n=970)		Patients with early RA (n=481)
Unadjusted model	Adjusted model	Unadjusted model	Adjusted model
ACPA status at baseline
ACPA neg/RF neg	Ref	Ref	Ref	Ref
ACPA neg /RF pos	−1.19 (1.01), 0.24	0.48 (0.73), 0.51	−1.68 (1.37), 0.22	−0.33 (1.01), 0.74
ACPA pos /RF neg	−2.96 (1.29), 0.02	−0.63 (0.94), 0.50	−4.15 (1.93), 0.03	−1.72 (1.44), 0.02
ACPA pos /RF pos	−2.73 (0.69),<0.0001	−1.63 (0.50), 0.001	−3.00 (0.95), 0.002	−2.27 (0.71), 0.002
Time (month)	−0.15 (0.01),<0.0001	−0.15 (0.004),<0.0001	−0.18 (0.01),<0.0001	−0.18 (0.005),<0.0001
Female	0.73 (0.70), 0.30	1.91 (0.51), 0.0002	1.28 (0.92), 0.17	2.14 (0.69), 0.002
Age at baseline	−0.02 (0.02), 0.34	−0.02 (0.02), 0.23	−0.01 (0.02), 0.66	−0.01 (0.02), 0.72
CDAI at baseline	0.43 (0.02),<0.0001	0.43 (0.02),<0.0001	0.39 (0.02),<0.0001	0.39 (0.02),<0.0001

Adjusted model is adjusted for age, sex, time, and CDAI at baseline.

Bold values indicate statistically significant.

ACPA, anticitrullinated protein antibody; CDAI, Clinical Disease Activity Index; GLMMs, Generalised Linear Mixed Models; RA, rheumatoid arthritis; RF, rheumatoid factor.